Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
551 results about "Early rheumatoid arthritis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Persistent stiffness, tenderness, and pain in joints may be an early sign of rheumatoid arthritis. Another early sign of RA is joint stiffness. Stiffness may occur in one or two small joints, often in the fingers.
Uses and compositions for treatment of rheumatoid arthritis
InactiveUS20080131374A1Improve the quality of lifeBiocideAntipyreticAntigen bindingEarly rheumatoid arthritis
The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.
Owner:MEDICH JOHN R +7
Uses and compositions for treatment of rheumatoid arthritis
InactiveUS20120171123A1Improve the quality of lifeOrganic active ingredientsAntipyreticAntigen bindingEarly rheumatoid arthritis
The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.
Owner:MEDICH JOHN R +7
Application of parabacteroides merdae in treating or preventing rheumatoid arthritis or related diseases
ActiveCN104546934AAntipyreticBacteria material medical ingredientsArthritisEarly rheumatoid arthritis
The invention provides an application of parabacteroides merdae in treating or preventing rheumatoid arthritis or related diseases thereof, and also provides a pharmaceutical composition, a medicament, a food and a feed containing the parabacteroides merdae. By providing the parabacteroides merdae for animals, an anti-inflammatory effect can be effectively brought into play, the symptoms of rubefaction and swelling of joints can be effectively improved, and the symptoms of arthritis can be obviously relieved, so that the parabacteroides merdae can be effectively used for treating or preventing the rheumatoid arthritis or the related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1
Application of bacteroides ovatus in treating or preventing rheumatoid arthritis or related diseases thereof
InactiveCN104546932AEffective therapeuticEffectively prevent rheumatoid arthritisAntipyreticBacteria material medical ingredientsMedicineArthritis
The invention provides application of bacteroides ovatus in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides ovatus. Applied to animals, the bacteroides ovatus can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides ovatus can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1
Application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof
InactiveCN104546935AEffective therapeuticEffectively prevent rheumatoid arthritisAntipyreticBacteria material medical ingredientsMedicineBacteroides thetaiotaomicron
The invention provides application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides thetaiotaomicron. Applied to animals, the bacteroides thetaiotaomicron can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides thetaiotaomicron can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
InactiveUS8017121B2Peptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsSynovial CellEarly rheumatoid arthritis
There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor.The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.
Owner:CHUGAI PHARMA CO LTD +1
Human t cell clone specific for rheumatoid arthritis
InactiveUS20020076725A1Microbiological testing/measurementBlood/immune system cellsAntigenSynovial Cell
A human T cell clone recognizing an antigen expressed by a synovial cell of a rheumatoid arthritis (RA) patient in HLA-DR-restricted manner is disclosed, which clone is very useful in exploring the pathogenesis of RA and developing a method for treating and preventing RA.
Owner:SHIONOGI & CO LTD
Application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof
The invention provides application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides dorei. Applied to animals, the bacteroides dorei can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides dorei can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1
Application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof
InactiveCN104546933AAntipyreticBacteria material medical ingredientsEarly rheumatoid arthritisRheumatoid arthritis
The invention provides an application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof, and also provides bacteroides caccae containing pharmaceutical compositions, medicaments, foods and feeds. By providing bacteroides caccae for animals, an anti-inflammatory effect can be effectively played, the symptoms such as redness and swelling of joints are effectively improved, and the symptoms of arthritis are obviously relieved, and therefore, the bacteroides caccae can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1
Application of common bacteroides in treatment or prevention of rheumatoid arthritis or related diseases thereof
The invention provides an application of common bacteroides in treatment or prevention of rheumatoid arthritis or related diseases thereof, and also provides common bacteroides containing pharmaceutical compositions, medicaments, foods and feeds. By providing common bacteroides for animals, an anti-inflammatory effect can be effectively played, the symptoms such as redness and swelling of joints are effectively improved, and the symptoms of arthritis are obviously relieved, and therefore, the common bacteroides can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1
Treatment of rheumatoid arthritis with FLIP antagonists
InactiveUS20050208151A1Organic active ingredientsPeptide/protein ingredientsInhibitor of apoptosisMedicine
The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that decreasing the activity of FLIP, an inhibitor of apoptosis, by at least 25% has a significant impact on the pathophysiology of rheumatoid arthritis. Inhibition of the activity of FLIP by at least 25% is predicted to alleviate the symptoms of rheumatoid arthritis.
Owner:ENTELOS INC
Blaster for treating rheumatoid arthritis
A Chinese medicine in the form of plaster for treating rheumatic arthritis, cervical spondylopathy, lumbar intervertebral disk protrusion, lumbar hyperosteogeny, etc is prepared from the Chinese-medicinal materials. Its advantages are simple preparing process, high curative effect, and short course of treatment.
Owner:吴立让
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. This invention also provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.
Owner:TEVA PHARMA IND LTD
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
InactiveUS20140120060A1Relieve symptomsBiocideOrganic chemistryTyrosine-kinase inhibitorEarly rheumatoid arthritis
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.
Owner:INFINITY PHARMA
Heated garment for medical applications
InactiveUS20140277220A1Promotes retention of heatRelieve symptomsElectrotherapyLight therapyPatient treatmentEarly rheumatoid arthritis
A patient-treatment system and related method provide relief from, and treatment for, muscle spasticity disorders, Willis-Ekbom disease, contracture, sleep onset insomnia, sleep maintenance insomnia, rheumatoid arthritis, and other similar disorders by applying controlled heat, and optionally muscle monitoring / stimulation, to one or more parts of a patient's body.
Owner:BIRCH TREE MEDICAL
Methods for the treatment of rheumatoid arthritis
InactiveUS20110189172A1Reduce the amount requiredReduce frequencyAntipyreticAnalgesicsRheumatoid arteritisEarly rheumatoid arthritis
Disclosed are compositions and methods for the treatment and / or prevention of rheumatoid arthritis, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.
Owner:XOMA US
Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in the differential diagnosis of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample both the concentration of anti-CCP and of antinuclear antibodies (ANA) correlating the concentrations determined to the diagnosis of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and ANA and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and ANA in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.
Owner:KLAUSE URSULA +4
Gene knockout carrier and gene knockout method of NLRP1 gene of MH7A cell
InactiveCN106755091AKnockout EfficientConvenient researchCell receptors/surface-antigens/surface-determinantsGenetically modified cellsSequence designInflammatory factors
The invention relates to the molecular biology field and particularly relates to a gene knockout carrier, a construction method and application thereof and a gene knockout method of an NLRP1 gene of an MH7A cell. A CRISPR-Cas9 gene knockout system is utilized for carrying out CRISPR targeting sequence design by taking NLRP1 as a target gene so as to prepare a knockout carrier aiming at the NLRP1 gene, and the knockout carrier is utilized for transfecting the MH7A cell, so that the NLRP1 gene in the MH7A cell can be efficiently knocked out; and therefore, a research platform for rheumatoid arthritis is effectively built, so that the research of the pathogenesis of the rheumatoid arthritis is greatly promoted, and the researches of the interaction of NLRP1 inflammasomes and various inflammatory factors and the disease related molecular mechanisms of the rheumatoid arthritis and meningitis can be promoted.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Methods of treating rheumatoid arthritis using il-17 antagonists
ActiveUS20130209480A1Inhibitory activityRapid improvement of clinical manifestationOrganic active ingredientsAntipyreticSecukinumabAntigen
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Owner:NOVARTIS AG
Human aggrecanase and nucleic acid compositions encoding the same
Human aggrecanase and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting aggrecanase activity in a host and methods of treating disease conditions associated with aggrecanase activity, e.g. rheumatoid arthritis, osteo-arthritis, infectious arthritis, gouty arthritis, psoriatic arthritis, spondolysis, sports injury, joint trauma, pulmonary disease, fibrosis, and the like.
Owner:SYNTEX (USA) INC
Epitope of rheumatoid arthritis and application thereof
The invention discloses an epitope of rheumatoid arthritis and application thereof, belonging to the technical field of immunologic diagnosis. The epitope is a polypeptide, and the amino acid sequence is disclosed as SEQ ID NO:1 in the sequence table. ELISA detection and patient serum reaction condition indicate that the epitope polypeptide can be specifically combined with IgG in the patient serum, and does not react with the serum of a health person. The epitope polypeptide can be used for preparing medicines for diagnosing rheumatoid arthritis.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA +1
Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease
InactiveCN1561994ASafe and effective treatmentOrganic active ingredientsAntipyreticDiseaseImmunologic disorders
A composite medicine for treating the umatoid arthritis and autoimmune disease contains the sweet worm wood herb's extract (dihydroarteannuin, artesumate, artemether, etc).
Owner:齐岩 +1
Aminopyridazinone compounds as protein kinase inhibitors
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Traditional Chinese medicine for treating rheumatoid arthritis
InactiveCN101979074AEasy to prepareReasonable preparationAntipyreticAnalgesicsMedicinal herbsSide effect
The invention relates to a traditional Chinese medicine for treating rheumatoid arthritis. The traditional Chinese medicine consists of the following raw material medicaments by weight: 9 to 20 grams of incised notopterygium rhizome, 6 to 12 grams of divaricate saposhnikovia root, 3 to 9 grams of prepared liquoric root, 9 to 20 grams of heracleum, 9 to 30 grams of Chinese taxillus twig, 6 to 18 grams of root of largeleaf gentian, 9 to 18 grams of Chinese angelica, 6 to 9 grams of cassia twig, 6 to 18 grams of achyranthes root, 6 to 15 grams of turmeric, 9 to 30 grams of mulberry twig and 9 to 18 grams of eucommia bark. The traditional Chinese medicine of the invention has simple and reasonable formula, wide medicinal herbs resource, low cost, remarkable curative effect and clinical application effective rate of 83.2 percent, does not have toxic or side effect, and is convenient to use.
Owner:苏桂华
Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
The present invention pertains, at least in part, to substituted tetracycline compounds. The present invention also pertains to methods for treating rheumatoid arthritis in a subject, comprising administering to the subject a tetracycline compound of the invention.
Owner:MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO PC
Anti-EDB antibody-targeted IL-10 cytokine for therapy of rheumatoid arthritis
InactiveUS8404814B2Improve stabilityHigh affinityPeptide/protein ingredientsAntipyreticOncofetal fibronectinRheumatoid arteritis
The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumors or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.
Owner:PHILOGEN SRL LLC
Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
InactiveUS9643967B2Useful in treatmentOrganic active ingredientsOrganic chemistryInflammatory Bowel DiseasesAutoimmune disease
The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7 / 8, TLR7 / 9 or TLR7 / 8 / 9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
![Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors](https://images-eureka.patsnap.com/patent_img/ad6747b1-7056-4231-b2a4-e2bbf5d791d5/US09643967-20170509-D00001.png "Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors")
![Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors](https://images-eureka.patsnap.com/patent_img/ad6747b1-7056-4231-b2a4-e2bbf5d791d5/US09643967-20170509-D00002.png "Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors")
![Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors](https://images-eureka.patsnap.com/patent_img/ad6747b1-7056-4231-b2a4-e2bbf5d791d5/US09643967-20170509-D00003.png "Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors")
Owner:TAKEDA PHARMA CO LTD
Methods for determining and inhibiting rheumatoid arthritis associated with the braf oncogene in a subject
ActiveUS20120258461A1Reduce expressionReduce proliferationOrganic active ingredientsMicrobiological testing/measurementFibroblastContact inhibition
The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and / or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and / or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene.
Owner:UNITED STATES OF AMERICA
Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
InactiveUS20130209463A1Less frequent dosingReduce riskBiocideSenses disorderImmune modulatorAutoimmune disease
This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
Owner:COMPUGEN
Macrolide derivatives
InactiveUS20090076253A1Strong inhibitory activityAntibacterial agentsOrganic active ingredientsRESPIRATORY DISTRESS SYNDROME ADULTLymphatic Spread
Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).
Owner:TAISHO PHARMACEUTICAL CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com